Gaia Schiavon
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Population Pharmacokinetics and Exposure-Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer.
Journal: Clinical and translational science
Published: March 13, 2025
An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.
Journal: Cancer chemotherapy and pharmacology
Published: November 18, 2024
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.
Journal: Future oncology (London, England)
Published: September 16, 2024
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
Journal: Breast cancer (Tokyo, Japan)
Published: July 09, 2024
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: May 31, 2023
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 15, 2022
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: March 28, 2022
Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer.
Journal: PloS one
Published: February 01, 2022
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Journal: Molecular oncology
Published: August 09, 2021
Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.
Journal: British journal of clinical pharmacology
Published: March 31, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Journal: NPJ breast cancer
Published: October 08, 2020
Last Updated: 09/26/2026